# InventisBio

Source: https://onco.cc/companies/inventisbio/  
OnCo record `inventisbio` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

InventisBio developed garsorasib, one of the two KRAS G12C pills approved in China in 2024, and the third-generation EGFR inhibitor befotertinib.

## Summary

InventisBio, based in Shanghai, founded in 2013 and listed as 688382.SS, developed garsorasib, one of the two KRAS G12C tablets approved in China in 2024, and the third-generation EGFR inhibitor befotertinib. Garsorasib, or D-1553, was approved in August 2024, befotertinib, or D-0316, was approved in 2023 through Betta Pharmaceuticals for EGFR-mutant non-small-cell lung cancer, and earlier programmes covered gout and oestrogen receptor degraders. OnCo links it to garsorasib and to Betta Pharmaceuticals. Whether a second domestic KRAS G12C inhibitor can differentiate from the other in the same market is the open question. Garsorasib has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- Also known as: 益方生物
- Tags: china
- HQ: Shanghai
- Type: biotech
- Website: https://www.inventisbio.com/
- Ticker: 688382.SS

## Sources

- Official website: https://www.inventisbio.com/

## Connected records

- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- drugs: [D-0502](https://onco.cc/drugs/d-0502/), [Garsorasib](https://onco.cc/drugs/garsorasib/), [IN10018](https://onco.cc/drugs/in10018/)
- companies: [Betta Pharmaceuticals](https://onco.cc/companies/betta/)
- trials: [A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer](https://onco.cc/trials/nct06954961/), [a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors](https://onco.cc/trials/nct06166836/), [Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors](https://onco.cc/trials/nct05379946/), [Study to Evaluate D-1553 in Subjects With Solid Tumors](https://onco.cc/trials/nct04585035/)

---
JSON: https://onco.cc/api/v1/entities/inventisbio.json